ClinicalTrials.gg
CompletedNCT00770445PIOcombUpdated Aug 18, 2010

Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.

A Phase 4 interventional study of Pioglitazone and insulin and Pioglitazone and metformin and insulin in Diabetes Mellitus, sponsored by Takeda. Completed at 18 sites in Germany. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-08-18.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
53rd of 122
121 · median 103
Started
2008
with 12 others
Phase 4
57 of 122
4 open now
Registered
50th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 53rd largest by enrollment, is one of 13 that started in 2008, is one of 57 in phase 4, and was the 50th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the Anti-Inflammation Effects of Pioglitazone, twice daily (BID), and Pioglitazone/Metformin Combination Therapy BID in Type 2 Diabetes Subjects Treated with Insulin.

Read the detailed description

It is established that matrix metalloproteinases play an essential role in the degradation of collagen and other extra cellular matrix macromolecules. In addition, matrix metalloproteinases are implicated in plaque rupture through their capacity to thin the protective cap of the plaque, thus rendering it more vulnerable. In fact, matrix metalloproteinase-9 levels are elevated in patients with unstable plaques and in patients with acute coronary syndrome. In patients with type 2 diabetes mellitus, matrix metalloproteinase-1 and matrix metalloproteinase-9 levels are usually elevated and the atherosclerotic plaques are more vulnerable compared to non-diabetic patients, confirming the role of this proteinase in the development of acute coronary syndrome. Therefore, therapeutic strategies that reduce blood glucose levels and attenuate inflammation and matrix metalloproteinases activity may be a tool for reducing cardiovascular risk in patients with diabetes.

The purpose of this trial is to investigate whether the anti-inflammatory effects of pioglitazone are maintained and sustained over a longer observation period when given in combination with insulin in comparison to the metformin plus insulin combination. The duration of treatment for patients completing the study is approximately 6 months.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 121 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has Diabetes Mellitus type 2.
  • A glycosylated level greater than or equal to 6.5% and less than 8.5%.
  • Treatment with the following insulins with or without Oral Antidiabetic Therapy since 3 months:

    • Long acting basal insulin analogs
    • NPH insulin
    • Combination insulin with 1-2 daily doses except intensified insulin therapies.
  • A greater than or equal to 25.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Has a history of type 1 diabetes mellitus.
  • Has uncontrolled hypertension (systolic blood pressure greater than 160mmHg and/or diastolic blood pressure greater than 95mmHg) or change of antihypertensive treatment within the last 2 weeks.
  • Has acute infections.
  • Has anamnestic history of to the study drugs or to drugs with similar chemical structure.
  • Has a history of severe or multiple allergies.
  • History of drug or alcohol abuse in the past 5 years
  • A history of significant cardiovascular ( stage I - IV), respiratory, gastrointestinal, hepatic ( and/or Aspartate Aminotransferase greater than 2.5 times the reference range), renal (serum creatinine greater than 1.2 mg/dL in women and greater than 1.5 mg/dL in men, less than 60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator
  • History of macular edema.
  • State after kidney transplantation.
  • Serum potassium greater than 5.5 mmol/L.
  • History of primary hyperaldosteronism.
  • Acute myocardial infarction, open heart surgery or cerebral event (stroke/ Transitory Ischemic Attack) within the previous 12 months.
  • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Pre-treatment with gemfibrozil within the last 12 weeks.
    • Pre-treatment with rifampicin within the last 12 weeks.
    • Treatment with thiazolidinediones within the past 3 months.
    • If statin therapy applicable: Change of medication within the last 4 weeks.
    • Has used non-steroidal anti-inflammatory agents including low dose ASA or Cox-2-inhibitors if therapy has been initiated within the last 4 weeks.
    • Treatment with any other drug within 4 weeks before trial entry.
  • Any elective surgery during study participation.
  • Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.
  • History of dehydration, precoma diabeticorum or shock or diabetic ketoacidosis within the past year prior to screening visit.
  • Acute or scheduled investigation with iodine containing radiopaque material.
  • Uncontrolled unstable angina pectoris.
  • Medical history of acute and pericarditis, myocarditis, endocarditis, recent pulmonary embolism, hemodynamic relevant aortic stenosis, aortic aneurysm.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Pioglitazone 15mg BID

    Insulin therapy added

    Drug: Pioglitazone and insulin

  • Experimental
    Pioglitazone 15mg + Metformin 850mg BID

    Insulin Therapy Added

    Drug: Pioglitazone and metformin and insulin

  • Active comparator
    Metformin 850mg BID

    Insulin therapy added

    Drug: Metformin and insulin

Interventions

  • DrugPioglitazone and insulin

    Drug pages: Pioglitazone · Insulin

    Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.

    Also known as: ACTOS®

  • DrugPioglitazone and metformin and insulin

    Drug pages: Pioglitazone · Metformin · Insulin

    Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.

    Also known as: ACTOS®

  • DrugMetformin and insulin

    Drug pages: Metformin · Insulin

    Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.

07

What researchers measure

Primary outcomes

  1. Change from Baseline in Matrix Metallo Proteinase 9.

    The change between Matrix Metallo Proteinase 9 collected at final visit or week 24 and Matrix Metallo Proteinase 9 collected at baseline.

    Time frame: Baseline and Week 24.

Secondary outcomes

  1. Change from Baseline in 24-hour Blood Pressure Profile.

    The change between the 24-hour Blood Pressure Profile recorded at final visit or week 24 and 24-hour Blood Pressure Profile recorded at baseline.

    Time frame: Baseline and Week 24.

  2. Change from Baseline in Intima Media Thickness.

    The change between the value of Intima Media Thickness measured at final visit or week 24 and Intima Media Thickness measured at baseline.

    Time frame: Baseline and Week 24.

  3. Change from Baseline in 24-hour Urinary Sample.

    The change between the value of urine participants collect 24 hours before final visit or week 24 and urine participants collect 24 hours before baseline.

    Time frame: Baseline and Week 24.

  4. Change from Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide.

    The change between the value of N-terminal Pro-hormone Brain Natriuretic Peptide collected at final visit or week 24 and N-terminal Pro-hormone Brain Natriuretic Peptide collected at baseline.

    Time frame: Baseline and Week 24.

  5. Change from Baseline in 8-iso Prostaglandin F2 alpha.

    The change between the value of 8-iso Prostaglandin F2 alpha collected at final visit or week 24 and 8-iso Prostaglandin F2 alpha collected at baseline.

    Time frame: Baseline and Week 24.

  6. Change from Baseline in Albumin.

    The change between the value of Albumin collected at final visit or week 24 and Albumin collected at baseline.

    Time frame: Baseline and Week 24.

  7. Change from Baseline in Creatinine.

    The change between the value of Creatinine collected at final visit or week 24 and Creatinine collected at baseline.

    Time frame: Baseline and Week 24.

  8. Change from Baseline in C/A-quotient.

    The change between the value of C/A-quotient collected at final visit or week 24 and C/A-quotient collected at baseline.

    Time frame: Baseline and Week 24.

  9. Change from Baseline in Homeostasis Model Assessment - Insulin Sensitivity.

    The change between Homeostasis Model Assessment of Insulin Sensitivity collected at final visit or week 24 and Homeostasis Model Assessment of Insulin Sensitivity collected at baseline. Homeostatis Model Assessment measures insulin sensitivity, calculated by fasting insulin times fasting glucose, divided by a constant (22.5).

    Time frame: Baseline and Week 24.

  10. Change from Baseline in Total Cholesterol.

    The change between the value of Total Cholesterol collected at final visit or week 24 and Total Cholesterol collected at baseline.

    Time frame: Baseline and Week 24.

  11. Change from Baseline in Low-Density Lipoprotein.

    The change between the value of Low-Density Lipoprotein collected at final visit or week 24 and Low-Density Lipoprotein collected at baseline.

    Time frame: Baseline and Week 24.

  12. Change from Baseline in High-Density Lipoprotein.

    The change between the value of High-Density Lipoprotein collected at final visit or week 24 and High-Density Lipoprotein collected at baseline.

    Time frame: Baseline and Week 24.

  13. Change from Baseline in Triglycerides.

    The change between the value of Triglycerides collected at final visit or week 24 and Triglycerides collected at baseline.

    Time frame: Baseline and Week 24.

  14. Change from Baseline in Glycosylated Hemoglobin.

    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit or week 24 and Glycosylated Hemoglobin collected at baseline.

    Time frame: Baseline and Week 24.

  15. Change from Baseline in Glucose.

    The change between the value of Glucose collected at final visit or week 24 and Glucose collected at baseline.

    Time frame: Baseline and Week 24.

  16. Change from Baseline in Insulin.

    The change between the value of Insulin collected at final visit or week 24 and Insulin collected at baseline.

    Time frame: Baseline and Week 24.

  17. Change from Baseline in Intact Proinsulin.

    The change between the value of Intact Proinsulin collected at final visit or week 24 and Intact Proinsulin collected at baseline.

    Time frame: Baseline and Week 24.

  18. Change from Baseline in C-peptide.

    The change between the value of C-peptide collected at final visit or week 24 and C-peptide collected at baseline.

    Time frame: Baseline and Week 24.

  19. Change from Baseline in Adiponectin.

    The change between the value of Adiponectin collected at final visit or week 24 and Adiponectin collected at baseline.

    Time frame: Baseline and Week 24.

  20. Change from Baseline in High Molecular Weight Adiponectin.

    The change between the value of High Molecular Weight Adiponectin collected at final visit or week 24 and High Molecular Weight Adiponectin collected at baseline.

    Time frame: Baseline and Week 24.

  21. Change from Baseline in High-Sensitivity C-Reactive Protein.

    The change between the value of High-Sensitivity C-Reactive Protein collected at final visit or week 24 and High-Sensitivity C-Reactive Protein collected at baseline.

    Time frame: Baseline and Week 24.

  22. Change from Baseline in Fibrinogen.

    The change between the value of Fibrinogen collected at final visit or week 24 and Fibrinogen collected at baseline.

    Time frame: Baseline and Week 24.

  23. Change from Baseline in E-selectin

    The change between the value of E-selectin collected at final visit or week 24 and E-selectin collected at baseline.

    Time frame: Baseline and Week 24.

  24. Change from Baseline in Nuclear Factor-kappa B.

    The change between the value of Nuclear Factor-kappa B collected at final visit or week 24 and Nuclear Factor-kappa B collected at baseline.

    Time frame: Baseline and Week 24.

  25. Change from Baseline in Plasminogen Activator Inhibitor-1.

    The change between the value of Plasminogen Activator Inhibitor-1 collected at final visit or week 24 and Plasminogen Activator Inhibitor-1 collected at baseline.

    Time frame: Baseline and Week 24.

  26. Change from Baseline in Nitrotyrosine.

    The change between the value of Nitrotyrosine collected at final visit or week 24 and Nitrotyrosine collected at baseline.

    Time frame: Baseline and Week 24.

  27. Change from baseline in Insulin Consumption.

    The change between the value of Insulin collected at final visit or week 24 and Insulin collected at baseline.

    Time frame: Baseline and Week 24.

  28. Change from Baseline in Endothelial Function measured by Laser-Doppler-flowmetry.

    The change between the value of Endothelial Function measured at final visit or week 24 and Endothelial Function measured at baseline.

    Time frame: Baseline and Week 24.

  29. Change from Baseline in Body Weight.

    The change between the value of the participant's Body Weight recorded at final visit or week 24 and the participant's Body Weight recorded at baseline.

    Time frame: Baseline and Week 24.

  30. Change from Baseline in Electrocardiograms

    The change between the value of Electrocardiograms measured at final visit or week 24 and Electrocardiograms measured at baseline.

    Time frame: Baseline and Week 24.

  31. Change from Baseline in Alanine Aminotransferase Laboratory Safety Variable.

    The change between the value of Alanine Aminotransferase collected at final visit or week 24 and Alanine Aminotransferase collected at baseline.

    Time frame: Baseline and Week 24.

  32. Change from Baseline in Aspartate Aminotransferase Laboratory Safety Variable.

    The change between the value of Aspartate Aminotransferase collected at final visit or week 24 and Aspartate Aminotransferase collected at baseline.

    Time frame: Baseline and Week 24.

  33. Change from Baseline in Gamma-glutamyl transferase Laboratory Safety Variable.

    The change between the value of Gamma-glutamyl transferase collected at final visit or week 24 and Gamma-glutamyl transferase collected at baseline.

    Time frame: Baseline and Week 24.

  34. Change from Baseline in Glomerular Filtration Rate Laboratory Safety Variable.

    The change between the value of Glomerular Filtration Rate collected at final visit or week 24 and Glomerular Filtration Rate collected at baseline.

    Time frame: Baseline and Week 24.

  35. Change from Baseline in Alkaline Phosphatase Laboratory Safety Variable.

    The change between the value of Alkaline Phosphatase collected at final visit or week 24 and Alkaline Phosphatase collected at baseline.

    Time frame: Baseline and Week 24.

  36. Change from Baseline in Leucocytes Laboratory Safety Variable.

    The change between the value of Leucocytes collected at final visit or week 24 and Leucocytes collected at baseline.

    Time frame: Baseline and Week 24.

  37. Change from Baseline in Hemoglobin Laboratory Safety Variable.

    The change between the value of Hemoglobin collected at final visit or week 24 and Hemoglobin collected at baseline.

    Time frame: Baseline and Week 24.

  38. Change from Baseline in Thrombocytes Laboratory Safety Variable.

    The change between the value of Thrombocytes collected at final visit or week 24 and Thrombocytes collected at baseline.

    Time frame: Baseline and Week 24.

  39. Change from Baseline in Creatinine Kinase Laboratory Safety Variable.

    The change between the value of Creatinine Kinase collected at final visit or week 24 and Creatinine Kinase collected at baseline.

    Time frame: Baseline and Week 24.

  40. Change from Baseline in Creatinine Laboratory Safety Variable.

    The change between the value of Creatinine collected at final visit or week 24 and Creatinine collected at baseline.

    Time frame: Baseline and Week 24.

  41. Change from Baseline in Capillary Blood Glucose Laboratory Safety Variable.

    The change between the value of Capillary Blood Glucose collected at final visit or week 24 and Capillary Blood Glucose collected at baseline.

    Time frame: Baseline and Week 24.

  42. Change from Baseline in Potassium Laboratory Safety Variable.

    The change between the value of Potassium collected at final visit or week 24 and Potassium collected at baseline.

    Time frame: Baseline and Week 24.

  43. Change from Baseline in Circadian (7 point) Blood Glucose Profile (Week 24).

    The change between Circadian Blood Glucose measured before week 24 or final visit and Circadian Blood Glucose measured before baseline. Participants measure their blood glucose levels 7 times (before and after breakfast, before and after lunch, before and after dinner and before going to bed) on two arbitrary days and record these measurements in their diaries.

    Time frame: Baseline and Week 24.

  44. Change from Baseline in Circadian (7 point) Blood Glucose Profile (Week 12).

    The change between Circadian Blood Glucose measured before week 12 and Circadian Blood Glucose measured before baseline. Participants measure their blood glucose levels 7 times (before and after breakfast, before and after lunch, before and after dinner and before going to bed) on two arbitrary days and record these measurements in their diaries.

    Time frame: Baseline and Week 12.

08

Study locations

18 sites
  • Lichtenfels, Bavaria, Germany
  • Frankfurt, Hessen, Germany
  • Kassel, Hessen, Germany
  • Wiesbaden, Hessen, Germany
  • Bad Oeynhausen, North Rhine-Westphalia, Germany
  • Dinslaken, North Rhine-Westphalia, Germany
  • Duisburg, North Rhine-Westphalia, Germany
  • Essen, North Rhine-Westphalia, Germany
  • Münster, North Rhine-Westphalia, Germany
  • Wuppertal, North Rhine-Westphalia, Germany
  • Mainz, Rheinland-Pfalz, Germany
  • Diez, Rhineland-Palatinate, Germany
  • Landau, Rhineland-Palatinate, Germany
  • Dresden, Saxony, Germany
  • Leipzig, Saxony, Germany
  • Jena, Thüringen, Germany
  • Berlin, Germany
  • Hamburg, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
Start
May 2008
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Last update
Aug 18, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00770445
Lead sponsor
Takeda
First posted
Oct 10, 2008
Start date
May 2008
Primary completion
Jul 2010
Completion
Jul 2010
Last update
Aug 18, 2010

Study contacts

Medical Director
study director · Takeda Pharma GmbH, Aachen (Germany)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Insulin · Metformin

Start the discussion